G-Protein Coupled Receptor Family C, Group 5, Member A (GPRC5A) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Non-Small-Cell Lung Cancer

被引:44
|
作者
Fujimoto, Junya [1 ]
Kadara, Humam [1 ]
Garcia, Melinda M. [1 ]
Kabbout, Mohamed [1 ]
Behrens, Carmen [1 ]
Liu, Diane D. [2 ]
Lee, Jack [2 ]
Solis, Luisa M. [3 ]
Kim, Edward S. [1 ]
Kalhor, Neda [3 ]
Moran, Cesar [3 ]
Sharafkhaneh, Amir [4 ]
Lotan, Reuben [1 ]
Wistuba, Ignacio I. [1 ,3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Med, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA
关键词
Field cancerization; Chronic obstructive pulmonary disease; Non-small-cell lung cancer; g-protein coupled receptor family C; group; 5; member A; gene expression; TUMOR-SUPPRESSOR GENE; RETINOIC ACID; CHRONIC INFLAMMATION; INDUCTION; AIRWAY; TUMORIGENESIS; ACTIVATION; KNOCKOUT; SMOKING; SMOKERS;
D O I
10.1097/JTO.0b013e31826bb1ff
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Understanding oncogenes and tumor suppressor genes expression patterns is essential for characterizing lung cancer pathogenesis. We have previously demonstrated that mGprc5a/hGPRC5A is a lung-specific tumor suppressor evidenced by inflammation-mediated tumorigenesis in Gprc5a-knockout mice. The implication of GPRC5A in human lung cancer pathogenesis, including that associated with inflammatory chronic obstructive pulmonary disease (COPD), a risk factor for the malignancy, remains elusive. Methods: We sought to examine GPRC5A immunohistochemical expression in histologically normal bronchial epithelia (NBE) from lung disease-free never-and ever-smokers (n = 13 and n = 18, respectively), from COPD patients with (n = 26) and without cancer (n = 24) and in non-small cell lung cancers (NSCLCs) (n = 474). Quantitative assessment of GPRC5A transcript expression in airways (n = 6), adjacent NBEs (n = 29) and corresponding tumors (n = 6) from 6 NSCLC patients was also performed. Results: GPRC5A immunohistochemical expression was significantly lower in tumors compared to uninvolved NBE (p < 0.0001) and was positively associated with adenocarcinoma histology (p < 0.001). GPRC5A airway expression was highest in lung disease-free NBE, decreased and intermediate in NBE of cancer-free COPD patients (p = 0.004) and further attenuated and lowest in epithelia of COPD patients with adenocarcinoma and SCC (p < 0.0001). Furthermore, GPRC5A mRNA was significantly decreased in NSCLCs and corresponding NBE compared to uninvolved normal lung (p = 0.03). Conclusions: Our findings highlight decreased GPRC5A expression in the field cancerization of NSCLC, including that associated with lung inflammation. Assessment of the use of GPRC5A expression as a risk factor for NSCLC development in COPD patients is warranted.
引用
收藏
页码:1747 / 1754
页数:8
相关论文
共 11 条
  • [1] Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer
    Kuzumaki, Naoko
    Suzuki, Atsuo
    Narita, Michiko
    Hosoya, Takahiro
    Nagasawa, Atsumi
    Imai, Satoshi
    Yamamizu, Kohei
    Morita, Hiroshi
    Suzuki, Tsutomu
    Okada, Yohei
    Okano, Hirotaka James
    Yamashita, Jun K.
    Okano, Hideyuki
    Narita, Minoru
    PLOS ONE, 2012, 7 (10):
  • [2] PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD)
    F. Ng Kee Kwong
    A. G. Nicholson
    S. Pavlidis
    I. M. Adcock
    K. F. Chung
    BMC Cancer, 18
  • [3] PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD)
    Kwong, F. Ng Kee
    Nicholson, A. G.
    Pavlidis, S.
    Adcock, I. M.
    Chung, K. F.
    BMC CANCER, 2018, 18
  • [4] LEVELS AND PATTERNS OF ORPHAN-G-PROTEIN-COUPLED RECEPTOR, CLASS-C GROUP-5 MEMBER-D (GPRC5D) EXPRESSION IN NORMAL AND ABNORMAL PLASMA CELLS IN INDIAN MULTIPLE MYELOMA PATIENTS
    Jain, Disha
    Ghogale, Sitaram
    Deshpande, Nilesh
    Patil, Jagruti
    Girase, Karishma
    Chatterjee, Gaurav
    Rajpal, Sweta
    Patkar, Nikhil V.
    Bagal, Bhausaheb
    Jain, Hasmukh
    Sengar, Manju
    Hasan, Syed Khizer
    Khattry, Navin
    Subramanian, Papgudi G.
    Gujral, Sumeet
    Tembhare, Prashant R.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2024, 46 : 48 - 48
  • [5] Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer (Dec, 10.1038/s41598-021-03139-5, 2021)
    Ajimizu, Hitomi
    Ozasa, Hiroaki
    Sato, Susumu
    Funazo, Tomoko
    Sakamori, Yuichi
    Nomizo, Takashi
    Kuninaga, Kiyomitsu
    Ogimoto, Tatsuya
    Hosoya, Kazutaka
    Yamazoe, Masatoshi
    Tsuji, Takahiro
    Yoshida, Hironori
    Itotani, Ryo
    Ueno, Kentaro
    Kim, Young Hak
    Muro, Shigeo
    Hirai, Toyohiro
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer
    Ji-Youn Han
    Eun Kyung Hong
    Byung Gil Choi
    Jin No Park
    Ki Won Kim
    Jin Hyung Kang
    Jong-Youl Jin
    Suk Young Park
    Young Seon Hong
    Kyung Shik Lee
    Medical Oncology, 2003, 20 : 355 - 362
  • [7] Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer
    Han, JY
    Hong, EK
    Choi, BG
    Park, JN
    Kim, KW
    Kang, JH
    Jin, JY
    Park, SY
    Hong, YS
    Lee, KS
    MEDICAL ONCOLOGY, 2003, 20 (04) : 355 - 362
  • [8] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [9] Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
    Mailankody, Sham
    Diamonte, Claudia
    Fitzgerald, Lisa
    Kane, Peter
    Wang, Xiuyan
    Sikder, Devanjan S.
    Senechal, Brigitte
    Bermudez, Vladimir P.
    Frias, Diana
    Morgan, Justina
    Grant, Patrick
    Purdon, Terence J.
    Hosszu, Kinga
    Devlin, Sean M.
    Shah, Urvi A.
    Landa, Jonathan
    Lesokhin, Alexander
    Korde, Neha
    Hassoun, Hani
    Tan, Carlyn
    Hultcrantz, Malin
    Shah, Gunjan L.
    Landau, Heather J.
    Chung, David J.
    Scordo, Michael
    Roshal, Mikhail
    Landgren, Ola
    Dogan, Ahmet
    Giralt, Sergio A.
    Park, Jae H.
    Riviere, Isabelle
    Brentjens, Renier J.
    Smith, Eric L.
    BLOOD, 2021, 138
  • [10] 3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy
    Sanz-Ortega, J
    Saez, MC
    Sierra, E
    Torres, A
    Balibrea, JL
    Hernando, F
    Sanz-Esponera, J
    Merino, MJ
    JOURNAL OF PATHOLOGY, 2001, 195 (04): : 429 - 434